Unaudited Standalone Financial Result of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenith Healthcare Limited reported unaudited standalone results for Q2 FY26 with revenue from operations of Rs. 226.66 lakhs, down sharply from Rs. 502.79 lakhs in Q2 FY25 — a drop of nearly 55%. Net profit for the quarter came in at Rs. 14.18 lakhs (EPS Rs. 0.026) versus Rs. 9.34 lakhs in the year-ago quarter, but on a much smaller revenue base. For the half-year (H1 FY26), revenue fell to Rs. 341.77 lakhs from Rs. 1,132.97 lakhs in H1 FY25, a steep ~70% decline, while net profit slipped to Rs. 12.30 lakhs from Rs. 24.59 lakhs. The company operates only in pharmaceutical trading as a single segment. Statutory auditors Doshi Doshi & Co issued an unqualified limited review report.
Sharp revenue contraction is the main concern — the top line has nearly halved year-on-year in Q2 and shrunk by two-thirds on a half-year basis, even as margins appear to have expanded on lower revenue. Shareholders should watch for sustained recovery in the trading business, as profitability gains on a shrinking base are not reassuring for long-term value.